Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 18/20 | 0.57 |
| ▸ | MMP2 | P08253 | 11/20 | 0.57 |
| ▸ | MMP3 | P08254 | 9/20 | 0.57 |
| ▸ | MMP8 | P22894 | 6/20 | 0.53 |
| ▸ | MMP9 | P14780 | 5/20 | 0.53 |
| ▸ | MMP7 | P09237 | 4/20 | 0.53 |
| ▸ | FCER2 | P06734 | 3/20 | 0.53 |
| ▸ | ADAM17 | P78536 | 2/20 | 0.49 |
| ▸ | MMP12 | P39900 | 1/20 | 0.49 |
| ▸ | MMP13 | P45452 | 1/20 | 0.49 |
| ▸ | MMP14 | P50281 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13986872 | 0.85 | MMP1 (0.63) | MMP1MMP2MMP3MMP8MMP9 | |
| SCHEMBL5886644 | 0.85 | MMP1 (0.63) | MMP1MMP2MMP3MMP8MMP9 | |
| SCHEMBL7400674 | 0.81 | PSMB5 (0.69) | MMP1MMP2MMP3MMP8MMP9 | |
| SCHEMBL6414154 | 0.79 | MMP1 (0.67) | MMP1MMP2MMP3MMP8MMP9 | |
| SCHEMBL7367573 | 0.79 | MMP1 (0.67) | MMP1MMP2MMP3MMP8MMP9 | |
| SCHEMBL22928874 | 0.79 | REN (0.71) | MMP1MMP2MMP3MMP8MMP9 | |
| SCHEMBL8510052 | 0.79 | PSMB5 (0.70) | MMP1MMP2MMP3MMP8MMP9 | |
| SCHEMBL7404473 | 0.79 | MMP1 (0.63) | MMP1MMP2MMP3MMP8MMP9 | |
| SCHEMBL6414037 | 0.78 | MME (0.74) | MMP1MMP2MMP3MMP8MMP9 | |
| SCHEMBL7268405 | 0.78 | MME (0.59) | MMP2MMP9MMP7MMP12MMP13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7468359-B2 | Compositions comprising oxophosphonate-based metalloproteinase inhibitors | YISSUM RESEARCH DEVELPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (US) | 2008-12-23 | — | — | US | disclosed |
| US-20060199787-A1 | COMPOSITIONS COMPRISING OXOPHOSPHONATE-BASED METALLOPROTEINASE INHIBITORS | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2006-09-07 | — | — | US | disclosed |
| US-7101864-B1 | Compositions comprising oxophosphonate-based metalloproteinase inhibitors | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2006-09-05 | — | — | US | disclosed |
| EP-1223945-A1 | COMPOSITIONS COMPRISING OXOPHOSPHONATE-BASED METALLOPROTEINASE INHIBITORS | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2002-07-24 | — | — | EP | disclosed |
| WO-2001026661-A1 | COMPOSITIONS COMPRISING OXOPHOSPHONATE-BASED METALLOPROTEINASE INHIBITORS | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2001-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060199787-A1 | COMPOSITIONS COMPRISING OXOPHOSPHONATE-BASED METALLOPROTEINASE INHIBITORS | ENPP1, MMP1, MMP9 | MMP1 2/4885MMP2 31/4885MMP3 21/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.